These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 34933307)

  • 21. Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.
    You C; Li Q; Qing L; Li R; Wang Y; Cheng L; Dong Z
    Int Urol Nephrol; 2024 Jan; 56(1):103-120. PubMed ID: 37659995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer.
    Tan X; Liu Z; Cai T; Wang Y; Wu Z; Qin Z; Li Z; Liu Z; Yuan G; Zhou Q; Yao K
    Eur Urol Oncol; 2024 Aug; 7(4):760-769. PubMed ID: 37884420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
    Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
    BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant Intravesical Chemotherapy Versus Immunotherapy for All Risk Groups of Patients With Non-muscle Invasive Bladder Cancer.
    Djug H; Hasukic S; Jagodic S; Ivanic D
    Med Arch; 2023; 77(6):460-464. PubMed ID: 38313102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study between mitomycin C versus Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer.
    Zaza MMA; Salem TAE; El-Sadat AM; Hassan Ali M
    Urologia; 2024 Feb; 91(1):61-68. PubMed ID: 37905506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.
    Massari M; O'Malley P; Benidir T; Su LM; Gao H; Crispen PL
    Urol Oncol; 2024 Sep; 42(9):289.e7-289.e12. PubMed ID: 38802293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC).
    Álvarez-Maestro M; Guerrero-Ramos F; Rodríguez-Faba O; Domínguez-Escrig JL; Fernández-Gómez JM
    Actas Urol Esp (Engl Ed); 2021 Mar; 45(2):93-102. PubMed ID: 33012593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
    Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
    Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Riedl C
    World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
    Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
    Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
    Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Okajima E; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
    World J Urol; 2024 Mar; 42(1):185. PubMed ID: 38512511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions.
    Durant AM; Choudry MM; Madura G; Mi L; Faraj KS; Tyson MD
    Urol Oncol; 2024 Jan; 42(1):21.e21-21.e28. PubMed ID: 37852817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?
    Abou Chakra M; Packiam VT; Duquesne I; Peyromaure M; McElree IM; O'Donnell MA
    Expert Opin Pharmacother; 2024 Feb; 25(2):203-214. PubMed ID: 38264853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
    Cochrane Database Syst Rev; 2021 Jun; 6(6):CD009294. PubMed ID: 34125951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive Role of the Systemic Immune Inflammation Index for Intravesical BCG Response in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer.
    Bolat D; Baltaci S; Akgul M; Karabay E; Izol V; Aslan G; Eskicorapci S; Sahin H; Turkeri L;
    Urol Int; 2023; 107(6):617-623. PubMed ID: 36809748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.